Why Skye Bioscience, Inc.’s (SKYE) Stock Is Down 7.80%
As of Monday, October 13, Skye Bioscience, Inc.’s SKYE share price has dipped by 7.80%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Commentary & Analysis
Why Skye Bioscience, Inc.’s (SKYE) Stock Is Up 5.72%
As of Wednesday, October 08, Skye Bioscience, Inc.’s SKYE share price has surged by 5.72%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Skye Bioscience, Inc.’s (SKYE) Stock Is Up 6.32%
As of Tuesday, October 07, Skye Bioscience, Inc.’s SKYE share price has surged by 6.32%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Skye Bioscience, Inc.’s (SKYE) Stock Is Down 58.11%
As of Monday, October 06, Skye Bioscience, Inc.’s SKYE share price has dipped by 58.11%, which has investors questioning if this is right time to buy.Tudor Pop
Why Skye Bioscience, Inc.’s (SKYE) Stock Is Up 5.51%
As of Thursday, October 02, Skye Bioscience, Inc.’s SKYE share price has surged by 5.51%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | SKYE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.4 | $219.9 | 4% |
|
| Shares Out (Mil) | 5.0 | 54.1 | 14% |
|
| Institutional Ownership | 93.8% | 92.9% | 64% |
|
| Float (Mil) | 3.1 | 41.4 | 8% |
|
| Beta | 2.99 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 26 | 522 | 23% |
|
| Price Change (52-week) |
(91.8%) | 44.7% | 5% |
|
| Growth | SKYE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (53.3%) | (10.1%) | 6% |
|
| EPS (5yr) | 28.3% | 15.8% | 80 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (33.7%) | (15.7%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 4 | |
| Current EPS | ($1.120) | ($5.040) | ($7.400) | |
| Month Ago EPS | ($1.120) | ($5.040) | ($7.400) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 2 | 2 | |
| Three Months Ago EPS | ($2.013) | ($8.368) | ($9.053) | |
| Year/Year Chg | (48.5%) | (55.3%) | (18.4%) | |
| Financials | SKYE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($51) | ($44) | 16% |
|
| EPS (TTM) | ($10.180) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($35) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $0 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $166 | 3% |
|
| Valuation | SKYE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.06 | na |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SKYE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (159.8%) | (47.5%) | 3% |
|
| ROE | (233.9%) | (52.7%) | 3% |
|
| Liabilities to Assets | 104.5% | 29.6% | 95% |
|
| F-Score | 2 | 3 | 7% |
|
Skye Bioscience, Inc. did not pass any screens on 11/6/2026.
